YM-202074
YM-202074 is a selective, allosteric metabotropic glutamate receptor type 1 (mGluR1) antagonist with high affinity. YM-202074 binds to the allosteric site of rat mGluR1 with a Ki of 4.8 nM. YM-202074 fumarate also inhibits mGluR1-mediated inositol phosphate production in rat cerebellar granule cells with an IC50 of 8.6 nM. YM-202074 has potent neuroprotective effects in transient MCA (tMCA) occlusion rat models.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 299900-83-7
- Formule: C22H30N4O2S
- Masse moléculaire:414.56
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
rat mGluR1 4.8 nM (Ki) |
YM-202074 significantly inhibits the mGluR1-mediated inositol phosphates production in rat cerebellar granule cells with an IC50 of 8.6 nM[1].
YM-202074 shows specific selectivity over other mGluRs, such as without agonistic nor antagonistic activity on mGluR2, mGluR3, mGluR4a, mGluR6 or mGluR7b (≤ 10 μM), but inverse agonistic activity on mGluR5 (10 μM) in HEK cells and CHO cells[1].
YM-202074 shows no affinity for ionotropic glutamate receptors (≤ 10 μM) and moderate off-target activity at a few receptors, such as with >60% inhibition of Adrenaline α2C receptor, dopamine transporter, acetylcholine M2/M4 receptor, sigma2 receptor, sodium channel site 2, and ≤ 50% inhibition of other 74 sites[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
YM-202074 (i.v. infusion, 10-20 mg/kg/h for 0.5 h followed by 2.5-5 mg/kg/h for 0.5-6 h) provides neuroprotection independent of nonspecific factors such as hypothermia, with no significant Physiological variables in tMCA occlusion rat models[1].
YM-202074 (i.v. infusion, 10-20 mg/kg/h for 0.5 h followed by 2.5-5 mg/kg/h for 23.5 h) dose-dependently improves neurological deficit and reduces the infarct volume in both the hemisphere and cortex in tMCA occlusion rat models, with potent efficacy in high dose[1].
YM-202074 (i.v. infusion, 20 mg/kg/h for 0.5 h followed by 5 mg/kg/h from 2 or 3 h to 24 h after tMCA occlusion) significantly maintains neuroprotection even when given 2 h after the onset of ischemia in tMCA occlusion rat models[1].
YM-202074 (i.v. infusion, 20 mg/kg/h for 0.5 h followed by 5 mg/kg/h from 2h to 24 h week after tMCA occlusion) notably sustains the improvement of neurological deficit and the reduction of infarct volume as well as increase of rat body weight for 1 week following the onset of ischemia in tMCA occlusion rat models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male SD rats firstly given a left jugular vein cannulation at the dorsal neck with chloral hydrate anesthesia (i.p., 350 mg/kg,), and 24 h later, a 3-0 poly-L-lysine-coated suture was advanced about 17 mm intracranially from the common carotid artery bifurcation via the right and internal external carotid artery with halothane (0.5-1.5%) for 3 h[1].
-
Dosage:10 or 20 mg/kg/h (loading infusion), 2.5 or 5 mg/kg/h (maintenance infusion)
-
Administration:i.v. infusion, loading infusion for 0.5 h followed by maintenance infusion for 23.5 h
-
Result:Dose-dependently improved neurological deficit and reduces the infarct volume in both the hemisphere and cortex in tMCA occlusion rat models.
Significantly reduced infarct volume in the hemisphere and the cortex by 55% and 70%, and improved neurological scores in tMCA occlusion rat models with 20 mg/kg/h for 0.5 h followed by 5 mg/kg/h for 23.5 h.
-
Animal Model:Male SD rats firstly given a left jugular vein cannulation at the dorsal neck with chloral hydrate Anesthesia (i.p., 350 mg/kg,), and24 h later, a 3-0 poly-L-lysine-coated suture was advanced about 17 mm intracranially from the common carotid artery bifurcation via the right and internal external carotid artery with halothane (0.5–1.5%) for 3 h[1].
-
Dosage:20 mg/kg/h (loading infusion), 5 mg/kg/h (maintenance infusion)
-
Administration:i.v. infusion, loading infusion for 0.5 h followed by maintenance infusion from 2 or 3 h to 24 h after tMCA occlusion, and then measured infarct volume of ischemic damage.
-
Result:Significantly maintained neuroprotection even when given 2 h after the onset of ischemia in tMCA occlusion rat models, with the degree of protection against hemisphere and subcortical infarct volume by 34% and 37%, respectively.
Notably sustained the improvement of neurological deficit and the reduction of infarct volume (especially cortex by 39%) as well as increase of rat body weight for 1 week following the onset of ischemia in tMCA occlusion rat models.
Chemical Information
-
CAS No. 299900-83-7
-
Masse moléculaire 414.56
-
Formule C22H30N4O2S
-
SMILES
O=C(N(C1CCCCC1)C)C2=CN3C4=C(C=CC(CN(CCOC)C)=C4)N=C3S2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
YM-202074 Related Classifications
HY-117132 Related Classifications
Powered by Bioz